Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis
(7h)
FDA Commissioner Marty Makary to resign, capping turbulent tenure: report
(10h)
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
(12h)
Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset
(13h)
AstraZeneca’s $800M bet undermined by immunogenicity in phase 3
(14h)
Charles River debuts AI diagnostic tool to cut down pathology timelines
(15h)
Bayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drug
(18h)
Roche nabs European approval for second Eli Lilly-partnered Alzheimer’s test
(19h)
Blood-based approach could detect early heart, kidney disease, study finds
(21h)
Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed
(21h)
Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data
(1d)
Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan
(1d)
Enterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled
(1d)
Quantum firm hailed by Amgen tech leader as an ‘extraordinary platform’ plans IPO
(2d)
New Hepta blood test could predict GLP-1 response
(3d)
Novo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotech
(4d)
Trump plans to fire FDA chief Marty Makary: report
(4d)
A protective gene sent to the liver cleared amyloid from mouse brains, sparking hope for an Alzheimer’s gene therapy
(4d)
Analysts cut enGene cancer sales forecast after updated data widen gap to JJ
(4d)
Odyssey voyages to Nasdaq with $304M IPO to fund autoimmune, inflammatory pipeline
(4d)
BioPharma Dive
FDA chief Marty Makary resigns from agency, ending tumultuous tenure
(9h)
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
(11h)
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
(15h)
A year after Vertex’s big launch, pain drug research faces a pivotal moment
(16h)
GSK cuts deal with Sino to broaden reach of hepatitis B drug
(1d)
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
(1d)
Biotech layoffs are easing, but is the worst over?
(1d)
The capacity crunch in biopharma is a location problem
(1d)
Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies
(1d)
Lilly to invest extra $4.5B across Indiana manufacturing
(4d)
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
(4d)
Lilly, Gilead lead pharma’s M&A boom
(4d)
Odyssey, on second try, snags $279M in an IPO
(5d)
Sarepta tumbles as its gene therapy sales decline further
(5d)
Angelini to buy Catalyst in $4B play for rare neuro drugs
(5d)
Entrada shares dive as Duchenne results disappoint
(5d)
Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B
(5d)
Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
(6d)
Novo hikes guidance on Wegovy pill’s fast sales start
(6d)
Avalo shares spike on skin drug data; BioNTech to cut staff
(6d)
Endpoints News
Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options
(5h)
EU reaches provisional deal on Critical Medicines Act
(10h)
FDA Commissioner Makary to resign, source says
(10h)
Iran war disruptions begin to emerge upstream of the pharma supply chain
(10h)
What I learned at a journalism fellowship about covering healthcare AI
(11h)
Five burning Qs for Isomorphic Labs after $2.1B raise for AI biotech
(12h)
Pfizer and Arvinas give disappointing breast cancer drug to Rigel
(12h)
Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
(13h)
Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal
(14h)
Knit Health raises $11.6M for 'fundamentally different' approach to healthcare AI
(14h)
Flagship startup, Serif, says it has solved non-viral gene therapy in monkeys
(17h)
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
(18h)
Optum Rx unveils pharmacy model with clear fees, building on transparency push
(1d)
Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
(1d)
Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push
(1d)
New home for Novo's Parkinson's cell therapy; GSK turns to China for hep B drug
(1d)
Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone
(1d)
Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win
(1d)
European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapy
(1d)
CSL sinks to nine-year low on revenue warning, $5B write-down
(1d)
BioSpace
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge
(14h)
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal
(15h)
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival
(16h)
FDA turns to old drugs to address new diseases, persistent medical needs
(16h)
Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls
(1d)
Makary’s reported FDA removal could be 'broad positive' for biopharma
(1d)
Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher
(1d)
Advances in RSV Vaccine Research and Development
(2d)
Merck, Amgen double down on bad cholesterol to vanquish number 1 killer
(2d)
Published FDA rejections point to manufacturing, data gaps as key stumbling blocks
(2d)
Trump signs off on plan to oust embattled FDA Commissioner Marty Makary: report
(4d)
Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy
(4d)
Lilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site
(4d)
Gilead sets blockbuster bar for Yeztugo’s first full year on the market
(4d)
Ascendis retreats to rare endocrinology wheelhouse as cancer plans falter
(4d)
FDA pilots AI-informed one-day facility inspections
(5d)
FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit
(5d)
Angelini inks $4.1B Catalyst buy to enter US rare disease market
(5d)
Gilead wipes out most of Arcellx workforce
(5d)
Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study
(5d)
STAT News
Why Marty Makary was the worst FDA commissioner in 25 years
(7h)
Males who discuss suicide seek help less often than females, report finds
(8h)
European Union inks a draft deal to boost local production of medicines and avoid shortages
(9h)
Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in
(10h)
Supreme Court extends mifepristone deadline
(11h)
Hims takes a $33 million hit from GLP-1 ‘pivot’
(11h)
Hims’ sales miss as telehealth competition grows
(11h)
STAT examines America’s deadliest drug
(13h)
We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
(14h)
Capsida says it still doesn’t know what caused gene therapy death
(15h)
In the battle of sepsis algorithms, performance alone doesn’t predict victory
(17h)
PCOS’s new name is PMOS, a small letter change that required a big scientific process
(18h)
Patients jockey for exemptions from Medicaid’s new work requirements
(19h)
Pharma and biotech leaders are destroying their own industry
(19h)
6 takeaways from STAT’s investigation into the U.S. alcohol epidemic
(19h)
Alcohol is wreaking havoc on U.S. public health. American society looks the other way
(19h)
Despite its toll, alcohol is still an awkward subject in the doctor’s office
(19h)
Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
(20h)
Supreme Court temporarily extends women’s access to a widely used abortion pill
(1d)
Colombia wins a key court ruling over a compulsory license issued for an HIV medicine
(1d)
BioPharma Trend
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(1d)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(4w)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(1mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(1mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(1mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(1mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(1mo)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(1mo)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(1mo)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(1mo)
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(1mo)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(1mo)
Bioptimus Launches Multimodal Tissue Atlas Across Three Continents
(1mo)
Merck Signs $20M Deal With Quotient to Find IBD Targets Using Somatic Genomics
(1mo)
insitro and Bristol Myers Squibb Add New AI-Found Targets in ALS Research
(1mo)
Latent Labs Launches AI Agent for Antibody Design From a Single Text Prompt
(1mo)
Earendil Labs Gets $787M to Push AI-Designed Antibodies Toward the Clinic
(1mo)
AI-Guided Brain Implant for Memory Loss Gets FDA Breakthrough Status
(1mo)
Dyno Launches Open-Source Agentic Protein Design Suite at GTC 2026
(1mo)
AlphaFold Database Now Includes Protein Pair Interactions
(1mo)
Drug Channels
340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar)
(17h)
The Hidden Costs of Over-Customizing Your Hub Technology Stack
(4d)
Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point
(1w)
Where Gross-to-net Pressure Actually Lives After Launch
(2w)
Drug Channels News Roundup, April 2026: PBM Specialty Pharmacy Steering, MLR Profit Shifting, Hospitals’ Fake Prices, and a Peek Behind the Scenes at DCI
(2w)
Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels
(3w)
Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care
(3w)
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground
(3w)
The Omnichannel Gap: Building the CRM of the Future for Patient Services
(3w)
The Hidden Pitfalls of Hub Transitions—and How to Navigate Them
(4w)
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update
(4w)
Informa Connect’s Life Sciences Pricing & Contracting USA
(4w)
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble (rerun)
(1mo)
The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel (rerun)
(1mo)
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)
(1mo)
Drug Channels News Roundup, Mid-April 2026: Vertical Integration & MLR Games, Copay Maximizers, Hospital Price Chaos, and One Big Drug Channel Family
(1mo)
The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)
(1mo)
Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26
(1mo)
Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo
(1mo)
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments
(1mo)
European Biotechnology Magazine
Infex raises £4.3M for anti-infective R&D ahead of Phase 2a data on lead asset
(16h)
EktaH links novel obesity drug to fat loss, muscle retention in early-phase trial
(19h)
Tolemy Bio raises €1.4m to build AI control panel for cell biology
(20h)
The DASbox® Mini Bioreactor System: Small scale. Big results
(2d)
Angelini inks $4.1B Catalyst takeover to fuel US expansion
(5d)
InflaRx attracts strong investor interest with US share offering turning to kidney
(5d)
Scarlet raises £3.2 million to advance lab-grown red blood cell therapies
(5d)
For several billions: Bayer adds Perfuse Therapeutics to portfolio of eye therapies
(6d)
Switzerland’s biotech sector defies tough markets with record revenue
(6d)
Macrocycles: big is the new beautiful
(6d)
Swiss Windward Bio adds US$165m to its Chinese pipeline
(1w)
Cytospire raises £61M to take gamma-delta T-cell engager into the clinic
(1w)
UCB buys Candid Therapeutics for up to US$2.2bn to deepen autoimmune T-cell engager push
(1w)
BioOrbit: record seed round for in‑space drug manufacturing
(2w)
Valneva reels in €84m in fresh financing to shore up vaccine pipeline
(2w)
Inside Servier’s new €200M venture fund
(2w)
Chiesi in US$1.9bn deal to buy KalVista and its angioedema drug
(2w)
Coultreon bags US$125m for autoimmune pipeline
(2w)
Astorg spins off Thermo Fisher’s microbiology arm
(2w)
CureVac takes Moderna to court over mRNA vaccine patents
(2w)
Drug Hunter
From Patient to Target: The Discovery of GDF15 in Hyperemesis Gravidarum
(12h)
Endometriosis Inspires Re-Examination of Known Targets at the Inaugural HERS Meeting
(1d)
Module 4, Section 3: Breakdown of Binding
(1d)
etripamil
(4d)
atirmociclib
(5d)
Metabolic Stability in Peptide Therapeutics
(6d)
EPSA: A Useful Metric Across Chemical Space
(6d)
infigratinib
(1w)
IAM1363
(1w)
Module 4, Section 2: All About Assays
(1w)
OP-3136
(2w)
varenicline
(2w)
Designing Selective SIK2 Inhibitors for Dual Anti-Inflammatory and Pro-Repair Effect in Inflammatory and Autoimmune Diseases
(2w)
March 2026 Patent Highlights
(2w)
March 2026
(2w)
GDC-4198
(2w)
Module 4, Section 1: Liganded Structures
(2w)
Alnodesertib
(3w)
zotatifin
(3w)
difamilast
(3w)
Labiotech.EU
Biotech risk management: The hidden risks behind layoffs
(14h)
The real reason CGT programs struggle to scale
(19h)
Inside CSL’s strategy to simplify a biotech giant
(1d)
The biggest biotech funding rounds in April 2026
(4d)
The rise of trispecific antibodies: Biopharma’s next big bet after bispecifics
(5d)
Making labs smarter for scientific breakthroughs
(5d)
Top biotech deals in April 2026
(6d)
Sickle cell disease after Casgevy: seven companies to watch in 2026
(6d)
Needle-free diabetes care: 6 devices that painlessly monitor blood sugar
(1w)
Five companies pushing biotech in Scotland
(2w)
How Epic Bio is leveraging CRISPR without cutting DNA
(2w)
When ADCs meet targeted protein degraders: The emerging field of degrader-antibody conjugates
(2w)
CAR-T cell therapies going in vivo
(2w)
Gilead’s pipeline strategy in 2026: A broadening focus beyond HIV
(2w)
AI in single-cell analysis: solving the interpretation gap
(2w)
Modified CRISPR tool targets Down syndrome mutation
(3w)
Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases
(3w)
AACR 2026: where is cancer therapeutics heading?
(3w)
PARP inhibitors: a proven class facing limits
(3w)
What new atopic dermatitis treatments are in the pipeline in 2026?
(3w)
Bio IT World
AI Framework for Differentiating Neurodegenerative Diseases
(22h)
Trends from the Trenches: The Capability Jump of AI and Its Impact
(6d)
Bacteria: Unsung Players in the Tumor Microbiome
(7d)
Much Progress Needed Planning Research to Consider Sex as a Biological Variable
(1w)
Craig Venter, Genomics Pioneer and Visionary, Dies
(2w)
Follow the Money: Autoimmune, Inflammatory Disease Therapies, Antibody-Drug Conjugates, AKT1-Selective Inhibitor Programs
(2w)
Bio-IT World Honors Four 2026 Innovative Practices Winning Projects
(2w)
Cepheid, Oxford Nanopore Expand Partnership, Revvity Launches New Platform, More
(2w)
fMRI-Based Mega-Study of Psychedelics Reveals Patterns of Brain Signaling Reorganization
(3w)
From Brain Implant to Lifelong Companion: Michel Maharbiz Unveils Epia Neuro
(3w)
Investors Sound Off on BCI Hype, Regulatory Risk, and the AI Gold Rush
(3w)
SPT Labtech and EMBL GeneCore Team Up for Fully Walkaway Automated Genomics Workflows
(4w)
AWS Launches Agentic Drug Discovery-Wet Lab Pipeline
(4w)
PARTAGE Method Reveals Genome Regulation in Single Approach
(4w)
CAS Releases Agentic Tool for Literature Discovery
(1mo)
'Mini-brain' Model Explores Concussion's Effects at Cellular Level
(1mo)
‘Humble’ AI Reveals When It is Uncertain in Diagnoses
(1mo)
Inductive Bio on a Winning Streak With ADMET Predictions
(1mo)
From Data to Discovery: Inside the Bio-IT Hackathon
(1mo)
Mapping the Trillion-Gene Universe: The Startup That Wants to Teach AI the Language of Life
(1mo)
GEN News
10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit
(1h)
AAVs in Focus: Practical Approaches to Capsid Analytics and Plasmid DNA Control
(7h)
Brain Histamine Map Links Genetic Factors to Mental Health and Psychiatric Disorders
(8h)
Acute Myeloid Leukemia Therapy Improved by CRISPR Stem Cell Transplant
(8h)
Stable Producer Cell Line Generation Platform Adds to VIVEbiotech’s Lentiviral Vector Manufacturing Capabilities
(1d)
Cholesterol Drug May Weaken Ovarian Cancer’s Metastatic Defense
(1d)
How HIV-1 Develops Resistance to Broadly Neutralizing Antibodies
(1d)
Genewiz Launches Gene Synthesis 2.0
(1d)
RegVelo AI Model Predicts Cell Fate, Tackles Developmental Disorders and Cancer
(1d)
StockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder Cancer Therapy
(2d)
Diabetes Drug Metformin’s Blood Glucose-Lowering Effects Tied to Action on Gut Cells
(2d)
How Digital Orchestration Is Redefining Regulatory Infrastructure for Cell and Gene Therapy
(4d)
Remembering J. Craig Venter, PhD
(4d)
ASGCT CEO David Barrett Previews the Upcoming Conference in Boston
(4d)
ParcelBio Unveils Programmable mRNA Platform Backed by $13M Financing
(4d)
Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy
(4d)
ASGCT Honors Mohamed Abou‑el‑Enein as Outstanding New Investigator
(4d)
Macrophages Use Cell Volume Changes to Sense Danger and Amplify Inflammation
(5d)
From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies
(5d)
G-Link CAR-T Delivery Platform Showcased at ASGCT
(5d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(1mo)
Understanding High-Risk Essential Thrombocythemia
(1mo)
Son’s Decision to Donate Gave His Father a Second Chance
(1mo)
Functional Precision Medicine Advances Brain Tumor Care
(1mo)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(1mo)
Choosing Motherhood Amidst Stage 4 Breast Cancer
(1mo)
FDA Approves Opdivo Combo for Newly Diagnosed Advanced Hodgkin Lymphoma
(1mo)
How Honest Conversations Strengthened a Couple After Cancer
(1mo)
Cardiac Health in Cancer Survivors: A Growing Need
(1mo)
Why Open Communication is Crucial for Patients With Multiple Myeloma
(1mo)
Understanding Mental Health Referrals in Cancer Care
(1mo)
Breast Cancer Early Detection: A Bold and Breastless Survival Story
(1mo)
Talzenna Plus Xtandi Delays Prostate Cancer Progression
(1mo)
Evolving Treatment Strategies Are Reshaping mCRPC Care
(1mo)
Pimicotinib Shows Early, Strong Tumor Response in Tenosynovial Giant Cell Tumors
(1mo)
Life After Liver Cancer: A Couple’s Journey of Recovery and Care
(1mo)
Why This Breast Cancer Survivor Chose "Flatness" After Implants
(1mo)
NCCN Guidelines Expand Options for Certain Bladder Cancer Patients
(1mo)
FOURLIGHT-1 Study Data Support Atirmociclib for HR+/HER2- Breast Cancer
(1mo)
Key Updates in Bladder, Kidney and Prostate Cancer from Experts
(1mo)
Contract Pharma
AOP Health, VRG Therapeutics Unite to Advance Inflammation and Immunology Target
(7h)
Ribo, Insilico Medicine to Partner on AI-Driven siRNA Drug Development
(9h)
Lonza Launches Xcite AAV Producer Cell Line Platform
(12h)
Boehringer Ingelheim Advances Partnership with Brainomix to Improve Pulmonary Fibrosis Care
(12h)
Quantitative Biosciences Institute Taps Dr. John Young as Chief Strategy Officer
(13h)
BMS, Hengrui Pharma Partner to Advance Early Stage Programs
(14h)
Aldevron, Minaris Renew Lentiviral Plasmid Agreement
(14h)
Colbert Packaging Unveils New Vision Inspection Hardware and Software
(1d)
Cellares, ProTgen to Automate Manufacturing of Novel Progenitor T-Cell Therapy
(1d)
Avid Bioservices Appoints Kerri McCullough Wood as Chief Commercial Officer
(1d)
Avalere Health Launches Japan Office
(1d)
Jean Luc Herbeaux Steps Down as CEO of Hovione
(1d)
CPTx Adds Edward Rebar as CSO, Promotes David Maier to CBO
(1d)
VIVEbiotech Adds EvoLVcell to Its Catalogue of LVV-Manufacturing Products
(1d)
Charles River Laboratories Introduces AI-Powered, End-to-End Workflow
(1d)
AGC Biologics Joins OXTL’s Clinical Development Network as a Manufacturing Partner
(1d)
Lilly to Invest an Additional $4.5B Across Two Indiana Sites
(1d)
Contract Pharma Sits Down with Jason Apter of Sannova Analytical
(2d)
Facility Overview: Scorpius BioManufacturing
(3d)
Minitabs™ Technology
(4d)
Pharma Times
Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
(17h)
SMC backs first-line metastatic bladder cancer combination after trial results
(18h)
Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
(1d)
Pulsesight reports positive phase 1 data for PST‑611 in dry AMD
(1d)
UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
(5d)
Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage
(5d)
Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
(1w)
MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
(1w)
Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
(2w)
Subcutaneous pembrolizumab begins rollout across NHS hospitals
(2w)
Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
(2w)
Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
(2w)
BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
(2w)
Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
(2w)
Theolytics announces first patient dosed in the Octopod‑IP trial
(2w)
UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention
(2w)
Saphnelo approved in the US for subcutaneous self‑administration
(2w)
Transgene completes randomisation in phase 2 trial of tg4050
(4w)
Bayer wins MHRA approval for Kerendia in heart failure
(4w)
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
(1mo)
Medcity News
How Healthcare Leaders are Reacting to the White House’s Proposed Fertility Benefit Rule
(5h)
Inviting Investors and Corporate Business Development Leaders to Bullseye
(8h)
Sanford Health Continues M&A Push with North Memorial Health Deal
(8h)
Bristol Myers, Hengrui Pharma Team Up in Global Drug Research Pact That Could Top $15B
(9h)
Five Ways Technology Can Transform Chronic Care Management
(13h)
AI in Transplant Diagnostics: Turning Complexity into Clinical Clarity
(14h)
Digital Fatigue: Healthcare’s Next Patient Experience Crisis
(14h)
How User-Generated Content is Transforming Pharma Insights on the Patient Experience
(15h)
About 67% of Employers Cover GLP-1s for Weight Management; That Could Decline in 2027
(1d)
How Beth Israel Lahey Health Cut Fax Failures From 34% to 4% — and Saved $4 Million
(1d)
A Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved Therapy
(1d)
Critical Care Documentation: Why It’s Different and How It Impacts Patient Care
(1d)
Listen Closer: What Triage Nurses Hear That Others Miss
(1d)
The Most Consequential Healthcare Market Structure Question of the Next Decade Is Sitting in a Comment Docket — It Closes June 9
(1d)
Autism Therapy is in Dire Need of a New Business Model
(1d)
Building a Unified Identity Strategy so Interoperability for Value-Based Care Can Succeed
(1d)
Was Mount Sinai’s Victory in a Dispute Over a Physician’s Credentialing Worth It?
(2d)
Windward Bio Secures $165M for Clinical Trials in Asthma, COPD & More
(2d)
DOJ Doubles Down on Healthcare Fraud Enforcement with New West Coast Strike Force
(2d)
States are Advancing Homecare’s Next Big Step — Paying Caregivers for Skill, Not Just Time
(2d)
Chemical & Engineering News
Marty Makary leaves a mixed legacy as FDA commissioner
(4h)
Helium supplies are tight—and it could get worse
(6h)
Business Watch: Massive complex planned for Abu Dhabi; Angelini to buy Catalyst for $4.1 billion
(7h)
Advances in imaging tools offer spatial biology for the AI age
(7h)
How a Canvas hack forced chemists to communicate creatively
(9h)
How cosmic dust forms from atoms in space
(11h)
Obituary: John Firkins
(15h)
Obituary: Charles T. Buse
(15h)
Letters to the editor on scientific sleuthing and lab safety
(1d)
Discarded jellyfish could be a sustainable collagen source
(1d)
Comment: Volunteering with purpose: Building skills, community, and belonging in ACS
(1d)
ACS Publications launches new environmental toxicology journal
(4d)
Policy Watch: EPA updates policy for publications by agency scientists
(4d)
These campaigners are fighting against shady refrigerant-gas practices
(4d)
These campaigners are fighting against shady refrigerant-gas practices
(4d)
Editorial: Distrust in science is not prevalent. We still need to address it
(4d)
Chemistry is elemental to music
(4d)
C&EN weekly chemistry news quiz, May 8
(4d)
Obituary: Peter H. Burghart
(4d)
Chemical tweaks to PHA make it more recyclable and tunable
(5d)
The Pharma Letter
Hengrui Pharma strikes $15.2 billion asset deal with BMS
(12h)
Strong start to 2026 for Lundbeck, with 21% revenue growth
(13h)
Bayer beats estimates to send shares higher
(13h)
FDA acts to make most of drug repurposing opportunities
(14h)
Cellular Intelligence acquires Novo Nordisk's cell therapy program for Parkinson's
(14h)
GSK inks hepatitis B collaboration with Sino Bio
(14h)
Higher dose Wegovy demonstrates nearly 28% weight loss
(15h)
DNA synthesis market forecast to top $30 billion by 2035
(16h)
Early data revive interest in OX40 immunotherapy
(17h)
Erasca partners with Merck on best-in-class pan-RAS molecular glue
(17h)
Early data revive interest in OX40 immunotherapy
(17h)
MacroGenics sells manufacturing arm to Bora in $123m deal
(18h)
AOP Health and VRG Thera partner on new immunology program
(18h)
Wall Street Journal raises new alarms about 340B
(18h)
Exciva appoints Mark Altmeyer as chairman
(18h)
MHRA strengthens safety warnings for finasteride and dutasteride
(1d)
Cytokinetics completes $805 million public offering
(1d)
Almirall shares slip despite results meeting estimates
(1d)
Nxera progresses out-licensing of GPCR-targeted program
(1d)
Daiichi Sankyo unveils new five-year business plan
(1d)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(1mo)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(1mo)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(1mo)
Treating Triple Negative Breast Cancer in the Frontline Setting
(1mo)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(1mo)
Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer
(1mo)
Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis
(1mo)
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy
(1mo)
Introducing CELMoDs into the Multiple Myeloma Treatment Paradigm
(1mo)
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
(1mo)
PSMA PET Applications in Prostate Cancer Management
(1mo)
FDA Confirms Potential Accelerated Path for Givastomig in GE Cancer
(1mo)
Deescalation vs Intensification: How to Ensure Patients Get the Treatment They Need
(1mo)
Deescalation Therapies in Breast Cancer Treatment
(1mo)
Prospective Data Support i31-SLNB Test to Guide Biopsy Use in Melanoma
(1mo)
LITESPARK-011 Signals Shifting Paradigm in RCC
(1mo)
Biomarkers, Oncolytic Viruses, and the Promise of Personalized Treatment for Glioblastoma
(1mo)
Priority Voucher Leads to Rapid Approval of Teclistamab in Myeloma
(1mo)
How ctDNA Testing is Changing Lymphoma Treatment
(2mo)
Symptom Burden, Functional Status, and Ongoing Challenges in Progressive Small Bowel Neuroendocrine Tumor
(2mo)
MedWatch
Analyst expects strong Vimkunya results after Bavarian's raised forecast
(14h)
WS Audiology puts faith in own brands despite Italian-Danish megadeal
(15h)
WS Audiology lags behind in key business area and goes all in on next wave of products
(15h)
Coloplast CFO on major write-down: "We've never seen anything like this"
(16h)
Lundbeck raises its full-year guidance
(16h)
Positive momentum for Bavarian, but double-digit jump unlikely, says analyst
(17h)
Hims & Hers plummets on weak earnings guidance
(18h)
US company gets the green light in Europe to conduct trials of GLP-1 gene therapy for type 2 diabetes
(18h)
Coloplast maintains reduced outlook for the year
(18h)
Novo's high-dose Wegovy shows greater efficacy
(20h)
WS Audiology maintains guidance after positive Q2 growth
(20h)
Novo Nordisk project closure draws Boston company to Copenhagen: Breaths new life into scrapped Parkinson's project
(21h)
Novo Nordisk shares have risen more than 30% since March
(21h)
Pfizer's major Canadian immunotherapy deal disappoints
(21h)
GSK signs China deal for hepatitis B treatment
(1d)
Trump plans to fire US FDA chief
(1d)
Ascendis sells specific US business unit for close to USD 200m
(1d)
GN partner move could reshape US hearing aid market: “A real game-changer"
(1d)
One disappointment after another: Coloplast has cleared the way for a new CEO
(1d)
Ascendis Pharma hits milestone posting EUR 25m profit
(1d)
In The Pipeline
More Vague, But More Useful
(5h)
Those Pesky Post Translational Modifications
(1d)
The Latest News in Vaccine Obstruction
(5d)
Ubiquitin Rides Again
(1w)
Helium and the Strait of Hormuz
(1w)
An Open Letter to Jay Bhattacharya
(2w)
The FDA Cracks Down on Tavneos
(2w)
The Latest Synthetic Automation Proposal
(2w)
No Heart Cancer? There's a Reason
(2w)
Fluorines As Reactive Handles, Eh?
(3w)
Progress Against Pancreatic Cancer, Part One
(3w)
Lyme Vaccines, Past and Possibly Future
(3w)
Bizarre Viruses Indeed
(3w)
Anti-Amyloid Antibodies for Alzheimer: You Already Know
(4w)
Antimalarial Drugs Stepping On Each Other's Toes
(4w)
Answers and Reasons and Knowing and Thinking
(4w)
Predicting Antibody Binding: No Champagne Just Yet
(4w)
Consider the Selfish Ribosome
(1mo)
New Bond Formations Just Keep On Coming
(1mo)
Ah, Peptides. Where to Begin?
(1mo)
Pharmaphorum
Reports: Makary out, Diamantas in as FDA commissioner
(9h)
Isomorphic raises $2.1bn for AI drug hunt
(12h)
Boehringer, Brainomix plan new trial of lung fibrosis AI
(14h)
EU agrees plan to tackle essential medicine shortages
(15h)
Novo says high-dose Wegovy can cause 28% weight loss
(16h)
BMS signs $15.2bn R&D alliance with China's Hengrui
(18h)
Cellular Intelligence scoops up Novo's Parkinson's therapy
(19h)
Novo Nordisk microRNA drug fluffs its lines in heart failure
(1d)
GSK taps enlists local aid for Chinese rollout of hep B drug
(1d)
GSK enlists local aid for Chinese rollout of hep B drug
(1d)
Deal finally unlocks NHS access to ITF's Duchenne drug
(1d)
Partner's Bizengri is first drug for rare, aggressive cancer
(1d)
Is Makary on the way out, and who might replace him?
(1d)
Capricor sues partner Nippon Shinyaku in DMD therapy spat
(4d)
Eisai, Biogen face delay to subcutaneous Leqembi
(4d)
J&J seeks to rewrite the script on depression treatment
(4d)
Windward raises $165m for TSLP drug, and other biofinancings
(4d)
Manufacturing hangover drives Daiichi Sankyo into the red
(4d)
Bayer plans filings for cardiac amyloidosis imaging agent
(5d)
Roche buys AI-powered diagnostics player PathAI
(5d)
Drug Discovery Weekly
Introducing Benchling Biologics: AI infrastructure for modern drug discovery (Americas Session)
(14h)
Introducing Benchling Biologics: AI infrastructure for modern drug discovery (Europe Session)
(14h)
How strong is the UK’s advanced therapy sector?
(14h)
Therapy for X-CGD shows early promise, Ensoma reports
(14h)
DDW Highlights: 12 May 2026
(16h)
University of Sheffield wins global prize for ALS project
(16h)
First GLP-1 gene therapy gets green light for diabetes trial
(17h)
CellCentric raises $220m to advance trials of oral myeloma drug
(18h)
Cyclic peptide drug design: From experimental discovery to AI-driven computation
(19h)
Congress extends Rare Pediatric Disease Priority Review Voucher programme through 2029
(1d)
AstraZeneca expands AI oncology collaboration with Immunai
(1d)
Angelini Pharma acquires Catalyst to enter US market
(1d)
Research suggests new treatment pathway for triple-negative breast cancers
(1d)
Cytospire raises £61m to advance T cell engager pipeline
(1d)
Rewriting the Oncology Playbook
(4d)
This week in Drug Discovery (4 – 8 May)
(4d)
Evotec nominates PDC for inflammatory skin disease programme
(4d)
FUJIFILM Biosciences and NextCell launch commercial platform
(4d)
Syngene announces leadership appointments to drive growth
(4d)
FDA fast tracks immune medicine targeting breast cancer
(4d)
HIT Consultant
Included Health Launches Provider Connect AI Assistant for High-Quality Physician Matching
(11h)
Labcorp Integrates Full Diagnostic Menu into Epic Aura: Streamlining Lab Workflows for U.S. Health Systems
(12h)
Medbridge Launches Outcomes Offering: Connecting Patient Care to Clinical Efficacy and Payment
(14h)
Evolution Devices Announces First Multi-Site Clinical Sale of EvoWalk to Sheltering Arms Institute
(14h)
1upHealth Deploys All CMS-0057-F Interoperability and Prior Authorization APIs Ahead of 2027 Deadline
(14h)
The $262B “Acceptance”: Why It’s Time to Stop Treating Denials as an Unavoidable Cost
(22h)
Basata Secures $21M to Rebuild Healthcare’s Operational Layer: Automating Referrals and Scheduling End-to-End
(1d)
Transforming Medical Coding Operations Through Hybrid Intelligence Design
(1d)
How Lucent and Tempus Are Using AI to Spot Alzheimer’s Earlier
(2d)
Withings Report Reveals Why Menopause is a Critical Cardiovascular Window
(4d)
Healthcare Cybersecurity Has Become an Operational Risk, Not Just a Security Function
(4d)
Follistatin-344: Myostatin Signaling, Tissue Plasticity, and Molecular Modulation Research
(5d)
MedTech Breakthrough Announces 2026 Award Winners: Celebrating a Decade of Health Technology Innovation
(5d)
Mid-Cycle Revenue Integrity: Leveraging Clinician-Governed AI to Reduce Denials and Understated Acuity
(5d)
Wisdom Ventures Closes $77.7M Fund II to Invest in AI-Native Wellbeing Startups
(5d)
Eko Health Appoints Dr. Steven Steinhubl as CMO to Drive Cardiac AI and Global Clinical Strategy
(5d)
Artera Launches AI Services Model and Agentic AI Squads for Specialty Care and FQHCs
(5d)
Elation Health Integrates New AHA and ACC PREVENT™ Cardiovascular Risk Standard
(5d)
Kanvas Biosciences Raises $48M to Advance Spatial Biology Platform and Immuno-Oncology Trials
(6d)
Fathom Secures Strategic Investment from CVS Health Ventures to Scale Autonomous Medical Coding
(6d)
Insights: Pink Sheet
White House MFN Push In Foreign Markets Could Backfire On US, Limit Access
(4h)
US FDA OTP Chief Says Cell And Gene Therapy CMC Readiness Remains Key Roadblock
(7h)
Germany Aims To Link Drug Rebates To Local R&D Activity
(8h)
Makary Goes: Embattled US FDA Commissioner Resigns Amid White House, Special Interest Anger
(9h)
EU Joint Clinical Assessments: Could Zepzleca, Imdylltra or Itvisma Be Next?
(12h)
US Supreme Court Extends Hold On Mifepristone In-Person Dispensing Ruling, Concerns Remain
(1d)
Stay Or Go? US FDA World Awaits Makary’s Fate, Agency Business Continues
(1d)
First-In-China Trials May Be ‘Counterproductive’ For Sponsors, US FDA CBER Official Says
(1d)
After Leucovorin Success, US FDA Eyes More Drug Repurposing
(1d)
EU Set To Introduce AMR Vouchers & Regulatory Sandboxes This Year
(1d)
Why Gene Therapy Trials Demand A Different Patient Engagement Playbook
(1d)
Singapore-Japan Pact Eyes Fewer Duplicative GMP Inspections, Faster Drug Access
(1d)
Sponsors’ ‘Funnel’ Mindset, Not US FDA Shifts, May Lead To Development Surprises
(4d)
Trump Plans To Oust Makary Clouds Future Of ‘Bold Reforms’ At US FDA
(4d)
Pink Sheet Podcast: US FDA’s Makary Pressured To Resign, Continues Hiring, Reform Efforts
(4d)
Good Communication From Companies Means Smoother EU-Level Joint Clinical Assessments
(4d)
Commercial Deal And Severity Modifier Help Secure English Funding For Duvyzat
(4d)
Fondiazone Telethon’s Waskyra ‘One Of The Best’ ATMP Submissions, EMA Advisor Says
(4d)
China Opens New Path For Novel Biomedical Technologies
(4d)
US FDA Shows Openness To Non-Traditional Methods In Gene Therapy CMC Flexibility Guidance
(5d)
BioXconomy
Compliance updates—False Claims Act, MFN, FDA clinical trial results and 340B
(6h)
Executive appointments in biopharma legal roles
(8h)
DOJ declares ‘war on fraud’ on pharma as enforcement priorities shift
(12h)
Parexel buys pharmacovigilance tech firm Vitrana in latest AI-focused deal
(13h)
Eyes on Asia: BeOne Medicines, Takeda, GSK
(17h)
Rosalind Davis talks pharma pricing shifts with new laws, other impacts
(17h)
Gen Z's AI paradox: Why the most tech-savvy generation trusts healthcare AI the least
(18h)
CEPI’s Pandemic Preparedness engine uses AI to predict the next outbreak
(1d)
CEPI’s Pandemic Preparedness engine uses AI to predict the next outbreak
(1d)
Columna Capital acquires Evidenze Group to expand CRO services across Europe
(1d)
Roche acquires PathAI for $750m upfront to advance AI-powered digital pathology
(1d)
Blackstone invests $250m to solve cystic fibrosis anagram
(1d)
DIY dosing: Experimental injectable peptides craze takes US by storm
(4d)
Blue Matter lands oversubscribed continuation fund from Baird Capital
(4d)
Odyssey raises $304m in upsized IPO, eyes Nasdaq debut
(4d)
Bayer expands ophthalmology portfolio with $2.45bn Perfuse acquisition
(4d)
Monoclonal antibody keeps pancreatic tumors at bay in clinical trial
(5d)
Better site payments mean better clinical trial partnerships
(5d)
It’s all about the brain: Angelini Pharma to buy Catalyst for $4.1bn
(5d)
GSK bets $1bn on fat-targeting RNA drug that could tackle the real killer in chronic disease
(5d)
BioCentury
Solving AAV’s one-and-done problem: ASGCT highlights
(1d)
Thin ice for Makary, redosing AAVs — a BioCentury podcast
(1d)
GSK takes rights to cardiovascular program from China-based SiranBio: Deals Report
(1d)
Entrada, enGene lose over half their value on clinical readouts
(1d)
Makary’s grip slips at FDA, triggering speculation on successor
(4d)
Odyssey completes journey to NASDAQ: Public Equity Report
(4d)
Tr1X: Inducing long-term immune tolerance with allogeneic Tr1 cells
(4d)
Enodia: Degrading secreted proteins before maturation
(4d)
Two mechanisms vie to deliver first hypoxic ischemic encephalopathy drug
(5d)
Mounjaro overtakes Keytruda for the first time
(5d)
CellCentric syndicate expands ahead of Phase III myeloma push: Venture Report
(5d)
Angelini builds U.S. commercial ops via $4.1B Catalyst acquisition
(5d)
Science Spotlight: New prime editing tools for large DNA insertions
(6d)
Aura names Natalie Holles CEO, and other biotech management moves
(6d)
The race for speed: Can Europe compete to be a bigger Phase I hub?
(6d)
FDA’s April approvals include slimmer label for Xpovio, two NMEs
(6d)
At least five PDUFA dates on FDA’s May docket
(1w)
Cytokinetics scores late-stage win in non-obstructive HCM as BMS plans Camzyos restart
(1w)
RevMed maps its next RAS frontier
(1w)
Europe’s Phase I trials see Spain, U.K. lead hot spots
(1w)
SCRIP
Makary’s Exit Resurrects Questions About US FDA’s Direction Under Trump Administration
(3h)
Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH
(5h)
Rigel Will Take Over Pfizer/Arvinas’s Recently Approved Veppanu
(5h)
Where No One Has Gone Before: Enterprise Targets ENaC Success With ETD001
(7h)
Scrip Awards Podcast: Call For Entries 2026, New AI Category, Triana Interview
(12h)
Bayer Back In The Market For Bolt-Ons
(13h)
Stock Watch: US Pharma Rescues Earnings Season As Lilly, AbbVie And BMS Beat
(17h)
Hengrui, BMS Strike Huge $15.2bn Alliance For Bundle Of Preclinical Assets
(18h)
Bridging The Reimbursement And Screening Gap: AstraZeneca’s Asia Strategy
(18h)
Hengrui/Braveheart’s Myosin Inhibitor Shows nHCM Disease-Modifying Signal
(19h)
Mounjaro Boosts Lilly’s Japan Sales But Price Cut Concerns Linger
(19h)
Gifrer Acquisition To Boost Celltrion’s French Reach, Portfolio
(1d)
LIB Launches Lerochol At Lower Direct-To-Patient Cost Than Other PCSK9 Drugs
(1d)
Daiichi Sankyo’s Oncology Strategy: 5 Years, 5 Drugs, Top 5 Cancer Companies
(1d)
Novo Nordisk Hands Parkinson’s Cell Therapy To Cellular Intelligence
(1d)
Liquidia And United Duke It Out In Treprostinil Market
(1d)
Almirall Hails Ebglyss Growth And Pipeline Advances
(1d)
Pipeline Watch: Six Approvals And Three Phase III Readouts
(1d)
Novo’s MicroRNA Therapy Disappoints In Post-Heart Attack Patients
(1d)
Korea Q1 Roundup: Hanmi Gears For Obesity Launch, Strong Growth For SK Biopharm
(2d)